1IA
ARQT icon

1620 Investment Advisors’s Arcutis Biotherapeutics ARQT Stock Holding History

1620 Investment Advisors’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.6K Sell
711
-164
-19% -$3.82K 0.01% 430
2026
Q1 		$20.6K Buy
+875
New +$22.3K 0.01% 397

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

1620 Investment Advisors's ARQT Position: Q2 2026 in Review

1620 Investment Advisors reduced its Arcutis Biotherapeutics (ARQT) stake by 19% in Q2 2026, selling an estimated $3.82K and leaving 711 shares worth $18.6K. The position accounts for 0.01% of the portfolio, ranked #430.

1620 Investment Advisors first reported a position in ARQT in Q1 2026 and has held it in 2 quarters since. The position peaked at $20.6K in Q1 2026. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • 1620 Investment Advisors held 711 shares of Arcutis Biotherapeutics worth $18.6K as of Q2 2026.
  • 1620 Investment Advisors sold 164 Arcutis Biotherapeutics shares in Q2 2026, an estimated $3.82K.
  • Arcutis Biotherapeutics made up 0.01% of 1620 Investment Advisors's portfolio in Q2 2026, its #430 holding.
  • 1620 Investment Advisors first reported a position in Arcutis Biotherapeutics in Q1 2026 and has held it in 2 quarters since.
  • 1620 Investment Advisors's Arcutis Biotherapeutics position peaked at $20.6K in Q1 2026.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on 1620 Investment Advisors's 13F filing for Q2 2026, filed 14 Jul 2026.